Serum Levels of S100A11 and MMP-9 in Patients with Epithelial Ovarian Cancer and Their Clinical Significance
Open Access
- 3 March 2021
- journal article
- research article
- Published by Hindawi Limited in BioMed Research International
- Vol. 2021, 1-5
- https://doi.org/10.1155/2021/7341247
Abstract
Objective. To investigate the serum levels of calgizzarin (S100A11) and matrix metalloproteinase-9 (MMP9) in patients with epithelial ovarian cancer (EOC) and determine their clinical significance. Methods. Serum levels of S100A11 and MMP9 were detected in patients with EOC, patients with benign ovarian tumor, and healthy women. The correlation between the two markers and clinicopathological characteristics of ovarian cancer was analysed. Results. The serum levels of S100A11 and MMP-9 in patients with EOC were higher than those in patients with benign ovarian tumor and in healthy women, and the expression levels of S100A11 and MMP-9 were positively correlated. S100A11 and MMP-9 were correlated with tumor staging, postoperative residual foci, ascites volume, serum CA125 level, chemotherapy response, and lymph node metastasis, while S100A11 and MMP-9 were not associated with the bilevel classification, histological type, age, and degree of differentiation. Conclusion. S100A11 and MMP-9 were both highly expressed in the serum of patients with EOC and were associated with cancer development, invasion, and metastasis. Therefore, they can be used as an important reference maker in the diagnosis and treatment of ovarian cancer.Keywords
Funding Information
- Projects of Medical and Health Technology Development Program (2016WS0279)
This publication has 25 references indexed in Scilit:
- Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content ScreeningInternational Journal of Molecular Sciences, 2013
- Tissue‐based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancerThe Journal of Pathology, 2012
- Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing TherapyEndocrinology, 2012
- Cancer Testis Antigens: Novel Biomarkers and Targetable Proteins for Ovarian CancerInternational Reviews of Immunology, 2011
- Over‐expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancerJournal of Surgical Oncology, 2011
- Current clinical use of biomarkers for epithelial ovarian cancerCurrent Opinion in Oncology, 2010
- Pseudopodial Actin Dynamics Control Epithelial-Mesenchymal Transition in Metastatic Cancer CellsCancer Research, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Ca2+-binding protein S100A11: A novel diagnostic marker for breast carcinomaOncology Reports, 2010
- Molecular cloning and expression of avian smooth muscle S100A11 (calgizzarin, S100C)Biochemistry and Cell Biology, 1997